 Cell Line, Tumor
"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 19 | 21 | | 2004 | 0 | 49 | 49 | | 2005 | 0 | 57 | 57 | | 2006 | 0 | 74 | 74 | | 2007 | 1 | 62 | 63 | | 2008 | 0 | 77 | 77 | | 2009 | 0 | 89 | 89 | | 2010 | 1 | 92 | 93 | | 2011 | 1 | 113 | 114 | | 2012 | 0 | 105 | 105 | | 2013 | 0 | 119 | 119 | | 2014 | 1 | 115 | 116 | | 2015 | 1 | 121 | 122 | | 2016 | 0 | 104 | 104 | | 2017 | 2 | 131 | 133 | | 2018 | 0 | 131 | 131 | | 2019 | 0 | 113 | 113 | | 2020 | 1 | 68 | 69 | | 2021 | 0 | 78 | 78 | | 2022 | 0 | 41 | 41 | | 2023 | 0 | 41 | 41 | | 2024 | 0 | 97 | 97 | | 2025 | 0 | 119 | 119 | | 2026 | 0 | 9 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ. Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer Res. 2026 Apr 02; 86(7):1605-1621.
-
Chen XL, Tharp KM, Ojalill M, Ozmadenci D, Boyer A, Haanen TJ, Lawson C, Lee HJ, Xia M, Tahon E, Zhang Y, Minor C, Khan SU, Anderson CC, Nemkov T, Rose M, Estrada MV, Molinolo AA, Warren E, Penalosa P, Eskander RN, McHale MT, Wang SE, Connolly DC, Fisch KM, Stupack DG, Schlaepfer DD. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Rep. 2026 Mar 24; 45(3):117009.
-
Martin-Martin A, Chipón C, Guzman-Kunstmann C, Guzman-Kunstmann S, Buelvas N, Henríquez C, Vidal F, Villarroel-Espindola F, Hinz TK, Heasley LE, López-Muñoz RA. The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation. Biol Res. 2026 Feb 19; 59(1).
-
Taylor ER, Proctor B, Vaurs M, Wu G, Mahieu M, Shrestha S, Morrison D, Weatherly L, Brelinsky S, Raghunandan M, Decottignies A, Arnoult N. Local heterochromatin enrichment promotes telomere clustering and PML nuclear body assembly at telomeres. Cell Rep. 2026 Mar 24; 45(3):117004.
-
Hoyt-Miggelbrink AM, Waibl Polania J, Wachsmuth L, Lorrey S, Mohan A, Hardigan A, Blandford E, Lerner E, Wilkinson D, Hotchkiss KM, Cook S, Hemmers S, Patel A, Ayasoufi K, Fecci P. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clin Cancer Res. 2026 Feb 17; 32(4):782-800.
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 Feb 02; 40(3-4):199-214.
-
Nelson CB, Wells JK, Kesarwani E, Sobinoff AP, Fernando M, Gao J, MacKenzie KL, Poulos RC, Nawaz U, Wang X, Ford HL, Pickett HA. Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems. Genes Dev. 2026 Feb 02; 40(3-4):267-283.
-
Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Watanabe A, Yang C, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells. 2026 Jan 05; 15(1).
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|